Update on targeted therapies in pediatric pulmonary arterial hypertension

被引：0
作者：
Bonnet, D. [1 ]
Levy, M. [1 ]
Bajolle, F. [1 ]
机构：
[1] Univ Paris 05, Hopital Necker Enfants Malades, Ctr Reference Malformat Cardiaques Congenit Compl, 149,Rue Sevres, F-75015 Paris, France
来源：
REANIMATION | 2013年 / 22卷 / 02期
关键词：
Pulmonary arterial hypertension; Endothelin receptor antagonist; Prostacycline; phosphodiesterase-5; inhibitor; Pediatrics;
D O I：
10.1007/s13546-012-0637-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Treatment of pediatric pulmonary arterial hypertension (PAH) has dramatically changed with the recent availability of specific oral drugs. These new treatments have been exclusively approved in PAH that should be differentiated from other causes of pulmonary hypertension particularly frequent in intensive care unit (ICU) patients. In pediatrics, data assessing efficacy and safety of these drugs do not exist in other settings than PAH. Consistently, these drugs are not recommended in persistent pulmonary hypertension of the newborn or during the postoperative course of cardiac surgery, even if routinely used. Treatment of PAH associated with congenital heart diseases represents a major concern and designing trials is challenging due to the possible benefits for children. Endothelin receptor antagonists and phosphodiesterase-5 (PDE-5) inhibitors have been approved in Europe for children use. Prostanoids including epoprostenol are largely used in the ICU, mostly by intravenous route. Specific PAH drugs may be used alone or in combination. Several trials are ongoing to test the best combination strategy with preliminary hopeful results suggesting significant improvement for the future. Creation of right-to-left shunts (atrioseptotomy and Potts' anastomosis) as well as lung transplantation should be indicated when children's clinical situation worsen despite optimal PAH pharmacological management.
引用
收藏
页码：S359 / S364
页数：6
相关论文
共 27 条
  • [1] Galie N., Hoeper M.M., Humbert M., Et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur Heart J, 30, pp. 2493-2537, (2009)
  • [2] Humbert M., Sitbon O., Chaouat A., Et al., Pulmonary arterial hypertension in France: Results from a national registry, Am J Respir Crit Care Med, 173, pp. 1023-1030, (2006)
  • [3] Galie N., Rubin L., Hoeper M., Et al., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial, Lancet, 371, pp. 2093-2100, (2008)
  • [4] Haworth S.G., Hislop A.A., Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006, Heart, 95, pp. 312-317, (2009)
  • [5] Berger R.M., Pulmonary hypertension associated with congenital cardiac disease, Cardiol Young, 29, pp. 1-4, (2009)
  • [6] Levy M., Maurey C., Celermajer D.S., Et al., Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease, J Am Coll Cardiol, 49, pp. 803-810, (2007)
  • [7] Palma G., Giodarno R., Russolillo V., Et al., Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery, Tex Heart Inst J, 38, pp. 238-242, (2011)
  • [8] Nemoto S., Sasaki T., Ozawa H., Et al., Oral sildenafil for persistent pulmonary hypertension early ater congenital cardiac surgery in children, Eur J Cardiothorac Surg, 38, pp. 71-77, (2010)
  • [9] Fraisse A., Butrous G., Taylor M.B., Et al., Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease, Intensie Care Med, 37, pp. 502-509, (2011)
  • [10] Widlitz A., Barst R.J., Pulmonary arterial hypertension in children, Eur Respir J, 21, pp. 155-176, (2003)
123